[go: up one dir, main page]

ATE278023T1 - Nicht humane, transgenische säugetiere mit sich entwickelnder neurologischer krankheit - Google Patents

Nicht humane, transgenische säugetiere mit sich entwickelnder neurologischer krankheit

Info

Publication number
ATE278023T1
ATE278023T1 AT95911583T AT95911583T ATE278023T1 AT E278023 T1 ATE278023 T1 AT E278023T1 AT 95911583 T AT95911583 T AT 95911583T AT 95911583 T AT95911583 T AT 95911583T AT E278023 T1 ATE278023 T1 AT E278023T1
Authority
AT
Austria
Prior art keywords
human
neurological disease
transgenic mammals
animal
developing neurological
Prior art date
Application number
AT95911583T
Other languages
English (en)
Inventor
Karen Hsiao
David R Borchelt
Sangra M Sisodia
Original Assignee
Univ Minnesota
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Minnesota, Univ Johns Hopkins filed Critical Univ Minnesota
Application granted granted Critical
Publication of ATE278023T1 publication Critical patent/ATE278023T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0312—Animal model for Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Environmental Sciences (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Physics & Mathematics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT95911583T 1994-01-27 1995-01-27 Nicht humane, transgenische säugetiere mit sich entwickelnder neurologischer krankheit ATE278023T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18906494A 1994-01-27 1994-01-27
PCT/US1995/001088 WO1995020666A2 (en) 1994-01-27 1995-01-27 Transgenic non-human mammals with progressive neurologic disease

Publications (1)

Publication Number Publication Date
ATE278023T1 true ATE278023T1 (de) 2004-10-15

Family

ID=22695766

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95911583T ATE278023T1 (de) 1994-01-27 1995-01-27 Nicht humane, transgenische säugetiere mit sich entwickelnder neurologischer krankheit

Country Status (8)

Country Link
US (1) US6262335B1 (de)
EP (1) EP0742831B1 (de)
JP (1) JPH09511388A (de)
AT (1) ATE278023T1 (de)
AU (1) AU1909695A (de)
CA (1) CA2182311A1 (de)
DE (1) DE69533583T2 (de)
WO (1) WO1995020666A2 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5586226A (en) * 1990-05-16 1996-12-17 Canon Kabushiki Kaisha Control method and device for a unicolor printer
US5877399A (en) * 1994-01-27 1999-03-02 Johns Hopkins University Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
US5789655A (en) * 1994-05-13 1998-08-04 The Regents Of The University Of California Transgenic animals expressing artificial epitope-tagged proteins
US5777194A (en) * 1995-04-26 1998-07-07 Cephalon, Inc. Gene-targeted mice with humanized Aβ sequence and Swedish FAD mutation
EP0832205A1 (de) * 1995-06-07 1998-04-01 Athena Neurosciences, Inc. Methode zur identifizierung von arzneimitteln gegen der alzheimer krankheit mittels transgener tiermodelle
US6717031B2 (en) 1995-06-07 2004-04-06 Kate Dora Games Method for selecting a transgenic mouse model of alzheimer's disease
WO1999009150A1 (en) * 1996-08-15 1999-02-25 Bayer Corporation Method of introducing modifications into a gene
GB9706463D0 (en) * 1997-03-27 1997-05-14 Medical Res Council A model of inflamation in the central nervous system for use in the study of disease
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US6710226B1 (en) 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US7179892B2 (en) * 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US6923964B1 (en) 1997-12-02 2005-08-02 Neuralab Limited Active immunization of AScr for prion disorders
US20030147882A1 (en) * 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) * 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
EP1248518A2 (de) * 2000-01-21 2002-10-16 PHARMACIA & UPJOHN COMPANY Transgenes mausmodell für neurodegenerative erkrankungen des menschen
EP2263453B1 (de) * 2000-06-20 2018-06-13 The Governing Council Of The University Of Toronto Transgenes Tiermodell für neurodegenerative Erkrankungen
US7371920B2 (en) * 2000-06-20 2008-05-13 The Governing Council Of The University Of Toronto Transgenic mouse model of neurodegenerative disorders
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
EP1764734A1 (de) * 2001-02-22 2007-03-21 Sony Corporation Inhaltbereitstellungs-/Erfassungssystem
GB0120344D0 (en) * 2001-08-21 2001-10-17 Smithkline Beecham Plc Compounds
US7479579B2 (en) * 2001-12-20 2009-01-20 The Regents Of The University Of California Triple transgenic mouse model of Alzheimer's disease
MY139983A (en) * 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
WO2003097674A1 (en) * 2002-05-17 2003-11-27 Pipeline Biotech A/S A purified polypeptide, isolated nucleic acids encoding said polypeptide, vectors and use thereof
US20060188512A1 (en) * 2003-02-01 2006-08-24 Ted Yednock Active immunization to generate antibodies to solble a-beta
TWI374893B (en) 2003-05-30 2012-10-21 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
ES2396555T3 (es) * 2004-12-15 2013-02-22 Janssen Alzheimer Immunotherapy Anticuerpos que reconocen péptido beta amiloide
TW200635607A (en) 2004-12-15 2006-10-16 Elan Pharm Inc Humanized Aβ antibodies for use in improving cognition
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
JP4942081B2 (ja) 2006-06-20 2012-05-30 独立行政法人理化学研究所 アルツハイマー病モデル動物およびその用途
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
PT2182983E (pt) 2007-07-27 2014-09-01 Janssen Alzheimer Immunotherap Tratamento de doenças amiloidogénicas com anticorpos anti-abeta humanizados
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
US8008539B1 (en) 2009-03-19 2011-08-30 University Of South Florida Generation of transgenic human soluble amyloid precursor protein alpha expressing mice
EP3004872B1 (de) 2013-06-04 2017-10-18 Virginia Commonwealth University Mda-9/syntenin-promotor zur abbildung und behandlung metastatischer krebszellen
EP3003022B1 (de) 2013-06-04 2017-11-22 Virginia Commonwealth University Verwendung eines trunkierten ccn1-promotors für krebsdiagnostik, therapeutika und theranostika

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
WO1989006689A1 (en) 1988-01-13 1989-07-27 The Mclean Hospital Corporation Genetic constructs containing the alzheimer brain amyloid gene
EP0451700A1 (de) 1990-04-10 1991-10-16 Miles Inc. Rekombinante APP Minigene zur Expression in Transgen-Mäusen als Alzheimer-Krankheitsmuster
JPH06507782A (ja) * 1990-06-15 1994-09-08 サイオス　ノバ　インコーポレイテッド アルツハイマー病のアミロイド形成開症状を示すヒト以外の組換え哺乳動物
JPH06502071A (ja) 1990-09-28 1994-03-10 ジ・アップジョン・カンパニー アルツハイマーのアミロイド前駆遺伝子を有するトランスジェニック動物
EP0568575B2 (de) 1991-01-21 2010-11-03 Elan Pharmaceuticals, Inc. Prüfung und modell für alzheimers-krankheit
US5672805A (en) 1991-07-18 1997-09-30 The Regents Of The University Of California Transgenic mice expressing the neurotoxic C-terminus of β-amyloid precursor protein
PT620849E (pt) 1992-01-07 2003-11-28 Elan Pharm Inc Modelos animais transgenicos para a doenca de alzheimer
US5604102A (en) 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
US5455169A (en) 1992-06-04 1995-10-03 Alzheimer's Institute Of America, Inc. Nucleic acids for diagnosing and modeling Alzheimer's disease
JPH09507746A (ja) 1993-10-27 1997-08-12 アテナ ニューロサイエンシズ，インコーポレイティド Ｓｗｅｄｉｓｈ変異を有するＡＰＰ対立遺伝子を含有するトランスジェニック動物
JPH07132033A (ja) 1993-11-12 1995-05-23 Hoechst Japan Ltd アルツハイマー病モデルトランスジェニック動物
US5877399A (en) * 1994-01-27 1999-03-02 Johns Hopkins University Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease

Also Published As

Publication number Publication date
WO1995020666A3 (en) 1995-09-28
DE69533583D1 (de) 2004-11-04
EP0742831B1 (de) 2004-09-29
EP0742831A1 (de) 1996-11-20
DE69533583T2 (de) 2005-10-06
JPH09511388A (ja) 1997-11-18
CA2182311A1 (en) 1995-08-03
US6262335B1 (en) 2001-07-17
AU1909695A (en) 1995-08-15
WO1995020666A2 (en) 1995-08-03

Similar Documents

Publication Publication Date Title
DE69533583D1 (de) Nicht humane, transgenische säugetiere mit sich entwickelnder neurologischer krankheit
ATE315085T1 (de) Transgene mäuse mit veränderter apolipoprotein e- expression und testverfahren.
EP0842266A4 (de) Transgenes schwein und schweinezellen, die humane hla-gene aufweisen
DE69123751D1 (de) Stall für tiere
BR9710652A (pt) Linhagens de célula de massa interna de célula derivadas de embriões de ungulados.
AU8768191A (en) Transgenic animals with alzheimer's amyloid precursor gene
DE69600581D1 (de) Tierzuchtvorrichtung
FI885054L (fi) Marin fiskodlingsanlaeggning.
NO881478L (no) Fiskeinnhegning for fiskeoppdrett.
DE60023451D1 (de) Aus nicht-menschlichen transgenen tieren gewonnene menschliche polyklonale antikörper
NO954483D0 (no) Inkubator for oppdrett av fiskeyngel
NO840376L (no) Merkonstruksjon for fiskeoppdrett.
EP0919122A4 (de) Tiermodel für hepatitis c erkrankungen
DE69728263D1 (de) Mit modifizierten h2-m transgene tiere
ATE407555T1 (de) Efficienter kerntransfer mit primordialen keimzellen
DE19780525D2 (de) Tierhaus für Kleintiere
ATE257173T1 (de) Thrombinrezeptor modifizierte transgene tiere
NO166751C (no) Anordning ved fiskeoppdrettsnett.
NO963341L (no) Oppdrettsmerd
DK0977838T3 (da) H2-O modificerede transgene dyr
FR2715533B1 (fr) Batterie de cages étagées pour l'élevage d'animaux, équipée d'une installation de séchage des excréments.
IT1210180B (it) Habitat etologico per allevamento di roditori ed altri animali acquatici.
ATE327324T1 (de) Herstellung von protein c in transgenen tieren
KR950022383U (ko) 수정란의 부화장치를 겸한 육추장치
SE9704878D0 (sv) An arrangement for and a method of managing a herd of animals

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties